Smoldering Multiple Myeloma
50
15
27
15
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
17 trials with published results (34%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
8.0%
4 terminated out of 50 trials
78.9%
-7.6% vs benchmark
6%
3 trials in Phase 3/4
113%
17 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 15 completed trials
Clinical Trials (50)
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
A Real-world Study in Participants With Smoldering Multiple Myeloma
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
Denosumab for Smoldering Multiple Myeloma
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Imaging in MGUS, SMM and MM